Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies

Journal of Nephrology

Volumn 28, Issue 5, 2015, Pages 623-631

  Mariano, Filippo ^a   Leporati, Marta ^b   Carignano, Paola ^c   Stella, Maurizio ^c   Vincenti, Marco ^b,d   Biancone, Luigi ^d  

^a CTO HOSPITAL   (Italy)

^b Centro Regionale Antidoping e di Tossicologia A Bertinaria   (Italy)

^c CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Colistin extracorporeal removal; Colistin sieving coefficient; Coupled plasmafiltration adsorption; CVVHDF; Hemoperfusion

Indexed keywords

COLISTIMETHATE; COLISTIN; COLISTIN A; COLISTIN B; UNCLASSIFIED DRUG; COLISTIN A, PAENIBACILLUS POLYMYXA JB05-01-1; COLISTIN B, PAENIBACILLUS POLYMYXA JB05-01-1;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BURN; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; DRUG ACCUMULATION; FASCIITIS; FEMALE; HEMOPERFUSION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MULTIPLE TRAUMA; PNEUMONIA; RENAL REPLACEMENT THERAPY; SEPTIC SHOCK; SYSTEMIC MYCOSIS; TANDEM MASS SPECTROMETRY; VERY ELDERLY; ACUTE KIDNEY INJURY; AGED; COMPLICATION; CRITICAL ILLNESS; FOLLOW UP; HEMODIAFILTRATION; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PROCEDURES; SHOCK, SEPTIC; SORPTION DETOXIFICATION;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, LIQUID; COLISTIN; CRITICAL ILLNESS; FEMALE; FOLLOW-UP STUDIES; HEMODIAFILTRATION; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; SHOCK, SEPTIC; SORPTION DETOXIFICATION;

EID: 84941194433     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0143-3     Document Type: Article

References (32)

1. Wareham DW, Bean DC, Khanna P et al (2008) Bloodstream infection due to Acinetobacter spp.: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 27:607–612
2. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589–601
3. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341
4. Bergen PJ, Landersdorfer CB, Zhang J et al (2012) Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis 74:213–223
5. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE (1970) Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72:857–868
6. Hartzell JD, Neff R, Ake J et al (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48:1724–1728
7. Collins JM, Haynes K, Gallagher JC (2013) Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 33:812–816
8. Sorlí L, Luque S, Grau S et al (2013) Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13:380
9. Li J, Rayner CR, Nation RL, Deans R et al (2005) Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49:4814–4815
10. Marchand S, Frat JP, Petitpas F et al (2010) Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 65:1836–1837
11. Garonzik SM, Li J, Thamlikitkul V, Paterson DL et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284–3294
12. Healy DP, Sombun AD, Gardner JC et al (2011) Pharmacokinetics of colistin in an adolescent boy with extensive burn injury. J Burn Care Res 32:e7–e11
13. Markou N, Fousteri M, Markantonis SL et al (2012) Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 67:2459–2462
14. Karvanen M, Plachouras D, Friberg LE et al (2013) Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 57:668–671
15. Honore PM, Jacobs R, Lochy S et al (2013) Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis 6:107–111
16. Luque S, Sorli L, Li J et al (2014) Effective removal of colistin methanesulphonate and formed colistin during intermittent hemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa. J Chemother 26:122–124
17. Ronco C, Inguaggiato P, D’Intini V et al (2003) The role of extracorporeal therapies in sepsis. J Nephrol 16(Suppl 7):S34–S41
18. Livigni S, Bertolini G, Rossi C, et al (2014) Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 4(1):e003536
19. Cruz DN, Perazella MA, Bellomo R et al (2007) Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 11(2):R47
20. Matzke GR, Aronoff GR, Atkinson AJ Jr et al (2011) Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int 80:1122–1137
21. Leporati M, Bua RO, Mariano F et al (2014) Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit 36:182–189
22. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign guidelines committee including the pediatric subgroup. surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
23. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 8:R204–R212
24. Mariano F, Tedeschi L, Morselli M, Stella M, Triolo G (2010) Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients. Intensive Care Med 36:1735–1743
25. Mariano F, Tetta C, Stella M, Miletto A, Triolo G (2004) Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption. Blood Purif 22:313–319
26. Plachouras D, Karvanen M, Friberg LE et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430–3436
27. Guideline on bioanalytical method validation (2011). European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (553 EMEA/CHMP/EWP/192217/2009)
28. Schmidt JJ, Hafer C, Clajus C et al (2012) New high-cutoff dialyzer allows improved middle molecule clearance without an increase in albumin loss: a clinical crossover comparison in extended dialysis. Blood Purif 34:246–252
29. Heilmann K, Keller T (2011) Polysulfone: the development of a membrane for convective therapies. Contrib Nephrol 175:15–26
30. Couet W, Grégoire N, Gobin P et al (2011) Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:875–879
31. Strunk AK, Schmidt JJ, Baroke E, Bode-Böger SM, Martens-Lobenhoffer J, Welte T, Kielstein JT (2014) Single- and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. J Antimicrob Chemother 69:2008 (Epub ahead of print) (PubMed PMID: 24651826)
32. Harm S, Falkenhagen D, Hartmann J (2014) Endotoxin adsorbents in extracorporeal blood purification: do they fulfill expectations? Int J Artif Organs 37:222–232